Formulation Development
Leriglitazone Marketing Authorization Application Submitted for Treatment of Cerebral Adrenoleukodystrophy Has Been Validated by EMA
Minoryx Therapeutics and Neuraxpharm Group recently announced the Marketing Authorization Application (MAA) for Minoryx’s lead candidate leriglitazone (NEZGLYAL) has been submitted to the European Medicines…
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development
Inotrem recently announced the publication of its precision medicine strategy for its leading drug candidate nangibotide, a first-in-class TREM-1 inhibitor in septic shock. This work…
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Ltd. recently announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The…
Arch Biopartners Announces Start of Patient Recruitment in Phase 2 Trial Targeting Drug-Toxin-Related Acute Kidney Injury
Arch Biopartners Inc. recently announced the investigator-led Phase 2 trial titled Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin (PONTIAK) has commenced patient recruitment…
etherna Achieves Major Milestones in its Bio-Reducible LNP Platform
etherna immunotherapies NV recently announced breakthrough innovation in efficient in vivo extrahepatic delivery of mRNA to several key tissues, including to hematopoietic and progenitor stem…
Abzena Appoints Geoffrey M. Glass as Chief Executive Officer
[caption id="attachment_146338" align="alignleft" width="160"] Geoffrey M. Glass[/caption] Abzena, a leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, recently announced Geoffrey M. Glass…
2025 Respiratory Drug Development e-Book - New Devices & Drugs Enhance Compliance & Facilitate Improved Disease Management
In this sixth annual Respiratory e-book, learn more about several companies and their contributions to inhalation drug delivery and device design.
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics, Inc. recently announced the first subjects have been dosed in a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for…
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
Tiziana Life Sciences, Ltd. recently announced compelling immunologic findings from the treatment of a moderate Alzheimer's Disease (AD) patient with intranasal foralumab. Transcriptional analysis of white…
ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia
ImCheck Therapeutics recently announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A)…
Longeveron Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Longeveron Inc. recently announced it has licensed an issued US patent (12,168,028 B2) for a stem cell technology from the University of Miami. The composition…
Sanner Celebrates Grand Opening of First US Production Facility in Greensboro, NC
Sanner officially opened its first US-based production facility in Greensboro, NC, just weeks after commencing initial operations. This marks a strategic milestone in the company’s…
UroGen Announces 5-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. recently announced the publication of results of a5-year long-term extension study of the Phase 2b OPTIMA II trial evaluating ZUSDURI (mitomycin) for…
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations Projected to be Early 2026
ArriVent BioPharma, Inc. recently announced that topline firmonertinib monotherapy data from the global pivotal FURVENT Phase 3 (NCT05607550) study in first-line EGFR exon20 insertion mutant…
Lexicon Announces Patient-Reported Data on Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals, Inc. recently announced data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of…
Lisata Therapeutics & WARPNINE Announce iLSTA Trial Enrollment Completion & Provide Preliminary Data Update
Lisata Therapeutics, Inc. and WARPNINE Incorporated recently announced the successful completion of patient enrollment in the Phase 1b/2a iLSTA trial (ACTRN12623000223639) in Australia. The study…
Gelteq Announces Agreement With IDT Australia to Secure Dedicated New Product Development & Manufacturing Facilities
Gelteq Limited recently announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility to…
Genascence Announces FDA Grants Regenerative Medicine Advanced Therapy Designation to GNSC-001 for Knee Osteoarthritis
Genascence Corporation recently announced the US FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy blocking interleukin…
Quetzal Therapeutics Debuts With Expert Leadership, High-Impact Pipeline & $50 Million of Committed Capital
Quetzal Therapeutics, a newly formed biopharmaceutical company, announced its official launch today with $50 million of committed capital. Founded to address urgent unmet needs in…
Cereno Scientific Announces Positive Topline Results From Phase 1 Trial of a Novel HDAC Inhibitor Supporting Advancement Into Phase 2
Cereno Scientific recently announced positive topline results from its Phase 1 trial of CS014, a novel HDAC inhibitor in development for idiopathic pulmonary fibrosis (IPF).…
